Kymeta Broadens Network Offerings for Government and Military Through Strategic Partnership with Comtech
8.6.2021 16:00:00 EEST | Business Wire | Press release
Kymeta (kymetacorp.com), the communications company making mobile global, announced today a strategic technology partnership with Comtech EF Data Corp. (comtechefdata.com), a leading provider of satellite communication equipment. The agreement enables Kymeta to broaden its network of offerings for the Kymeta™ u8 terminal through interoperability with Comtech’s SLM-5650B modem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005043/en/
The Kymeta™ u8 GO provides a complete connectivity solution for on-the-go communications when and where you need it. (Photo: Business Wire)
The pairing of the u8 antenna and Comtech modem using the Open Antenna to Modem Interface Protocol (OpenAMIP), an industry-wide open-source standard for antenna-router integration, allows for seamless integration and automatic operation through the use of both Low Density Parity Check (“LDPC”) waveforms and STANAG 4486 Edition 3, Annex E (EBEM) waveforms.
The Comtech SLM-5650B is a U.S. Army Forces Strategic Command (ARSTRAT) Wideband Global SATCOM certified modem for critical commercial backhaul, as well as government and military applications. It is fully compliant with MIL-STD-188-165A/B, complies with and supports FIPS 140-2 certified encryption.
Kymeta u8 terminals, antennas, and ODUs are easy to set up and acquire service within minutes of installation. The u8 is also available in a transportable configuration called the u8 GO, which is ideal for rapid deployments. The u8 GO enables safe transport with a hardened case for protection and provides a built-in car mount to support easy communications on the pause (COTP) and on the move (COTM).
“The integration of the u8 antenna with the Comtech modem allows users to upgrade to a SATCOM-on-the-move (SOTM) capability while utilizing existing modem and hub architecture,” said Neville Meijers, Kymeta Chief Strategy and Marketing Officer. “The ability to leverage existing network hardware while adding the SOTM capability will rapidly enhance unit capabilities. The low SWaP-C2 of the u8 terminal also makes it a perfect choice for upgrading legacy COTM terminals.”
“Comtech is very excited to expand our solution set and capabilities offered to our government and military user base,” said Fred Kornberg, Chairman of the Board and Chief Executive Officer of Comtech Telecommunications Corp. “The engineering, development, and testing of the mobility protocols between our widely fielded SLM-5650B satellite modem and Kymeta’s state-of-the-art u8 antenna expands the range of missions we can support and further demonstrates the flexibility and long-term developmental support our government and military users expect from our products.”
Kymeta’s next-generation solutions are built for mobility and designed to meet the needs of global defense agencies, government, public safety, and commercial customers. Kymeta’s products and services have been field deployed for over three years and received an overwhelmingly positive response from the industry. Kymeta’s new products and services offer a breakthrough in performance, ease of use, and affordability, and Kymeta anticipates that these solutions will further enhance its position in both commercial and government markets, further increasing its lead over competitive offerings.
This strategic technology partnership with Comtech follows a series of recently announced relationships to further expand Kymeta solutions and trainings for government and defense agencies and its Global TRANSEC Secure Network, which is available coverage in the U.S., Middle East, and Europe. Visit www.kymetacorp.com to learn more.
About Kymeta
Kymeta is unlocking the potential of broadband satellite connectivity, combined with cellular networks, to satisfy the overwhelming demand for comms on the move and making mobile global. Lepton Global Solutions, a Kymeta company, hosts the company’s satellite connectivity solutions and offers unique, complete, and turnkey bundled solutions to the market based on best-in-class technologies and tailored customer-centric services that meet and exceed customer mission requirements. These solutions in tandem with the company’s flat-panel satellite antenna, the first of its kind, and Kymeta Connect™ services provide revolutionary mobile connectivity on satellite and hybrid satellite-cellular networks to customers around the world. Backed by U.S. and international patents and licenses, the Kymeta terminal addresses the need for lightweight, slim, and high-throughput communication systems that do not require mechanical components to steer toward a satellite. Kymeta makes connecting easy – for any vehicle, vessel, or fixed platform.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005043/en/
Contact information
Business Inquiries for Kymeta:
Brenda Kuhns
Director of Marketing and Communications
Kymeta Corporation
bkuhns@kymetacorp.com
Media Inquiries for Kymeta:
Amanda Barry
Director PR & Content
The Summit Group
abarry@summitslc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom